However, these types of vaccines have yet to be used for commercial vaccine production. Another strategy that has been used for AHSV and other viral vaccines is the use of live viral vectors. These have the ability to introduce the recombinant gene product into the MHC class-I pathway of antigen presentation and therefore prime cytotoxic T cells as well as generate humoral immunity. Most recently, recombinant Venezuelan equine encephalitis virus-derived replicon vectors, individually expressing the VP2 and VP5 genes of AHSV-4, have been developed. However, in initial tests these constructs failed to induce neutralizing antibodies in horses. Our results indicated that there was latent SVCV in ornamental fish farms in northern China. Interestingly, during preparation of this manuscript, a research paper describing the complete genomic sequence of SVCV-A1 strain was published and the sequence was deposited in GenBank. For some reason, this sequence was withdrawn from the database. On the other hand, the three SVCV reference full length sequences used in the comparison were simply submitted by different researchers for the same virus. Some of the novel glioblastoma CNAs that we found are good examples of how our method improves on summary statistic approaches, such as RAE and GISTIC. For instance, the deletion of chromosome 15 has only been spotted on the q arm by RAE and GISTIC. When we examined the profile of the centroid of a cluster identified by our method, we saw a lower amplitude deletion on the p arm as well. Because of this low amplitude, each probe on its own would not have a significant mean deletion across the data set and would hence be missed by a summary statistic. However, because all of the probes for the chromosome are affected, the deletion should be considered a significant CNA and is readily identified by approach. As a second example, the deletion of the region 19q2-19q13.3 has not been found by other methods applied to the TCGA data set, even though it has been confirmed as a deletion event by previous studies. Here, the problem seems to be the fact that the same region is also present as an amplification event on a larger number of Gefitinib samples, which confounds the detection of this deletion by a summary test statistic. Finally, the deletion of the whole chromosome 21 is presumably missed by other methods because it is presents on only a small number of samples. However, since this event is a deletion of the whole chromosome and therefore supported on many probes, intuitively it should be much more statistically significant that a smaller but similarly infrequent event. Indeed, the importance of this CNA is confirmed by previous studies linking trisomy 21 in Down’s syndrome to lower prevalence of glioblastoma as well as by the correlation with the under-expression of a candidate tumor-supressor.